Lung Cancer最新文献

{"title":"Single-cell RNA-sequencing as a potential approach for studying intratumor heterogeneity in pleural mesothelioma.","authors":"Ania Alay, Raúl Marín, Elisabet Aliagas, Mireia Gausachs, Max Ruiz-Gil, Ivan Macia, Amaia Ojanguren, Susana Padrones, Eduard Dorca, Jesús Brenes, Ramón Palmero, Víctor Moreno, Holger Heyn, David Cordero, Ernest Nadal, Xavier Solé","doi":"10.1016/j.lungcan.2025.108679","DOIUrl":"10.1016/j.lungcan.2025.108679","url":null,"abstract":"<p><p>Pleural mesothelioma (PM) is a rare and lethal cancer with limited treatment options. Intratumor heterogeneity (ITH) has been postulated as one of the reasons for the poor treatment response observed in most PM patients. In this regard, we aimed to characterize ITH in a multi-site tumor specimen using single-cell RNA-sequencing (scRNA-seq).</p><p><strong>Methods: </strong>Tumor cells from three distant biopsies (costal, diaphragmatic, and mediastinal) of an epithelioid PM were analyzed with scRNA-seq.</p><p><strong>Results: </strong>Three main cell states were identified in all regions: C1, stem-like; C2, epithelial-like; and C3, mesenchymal-like. C1 state was the most prominent globally, although it was less abundant in the mediastinal biopsy, compared to the other two studied regions. Trajectory analysis was suggestive of an epithelial-mesenchymal plasticity dynamic, including a stem-like intermediate state. Signatures of upregulated genes in each state (SigC1, SigC2, SigC3) were obtained and assessed in a large cohort of PM samples. Patients with tumors enriched in SigC3 were associated with worse survival and with reduced sensitivity to standard of care PM regimens. Additionally, SigC1 appeared to be potentially more sensitive to anti-angiogenic therapies.</p><p><strong>Conclusions: </strong>This study highlights that scRNA-seq is useful to capture PM cellular and molecular heterogeneity and identifies gene-expression signatures with potential clinical relevance for future treatment tailoring.</p>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"207 ","pages":"108679"},"PeriodicalIF":4.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144812207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet study.","authors":"Rajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, Daniel C Christoph, Frank Griesinger, Martin Reck, Petra Hoffknecht, Jonas Kuon, Nikolaj Frost, Christian Grohé, Martin Faehling, Jingting Luan, Julia Roeper, Paolo Chesi, Miriam Blasi, Martin Kimmich, Till Olchers, Helge Bischoff, Laura V Klotz, Inn Chung, Petros Christopoulos, Michael Thomas","doi":"10.1016/j.lungcan.2025.108702","DOIUrl":"10.1016/j.lungcan.2025.108702","url":null,"abstract":"<p><strong>Background: </strong>Despite the approval of nivolumab/ipilimumab, the prognosis of patients with pleural mesothelioma (PM) remains poor. Although this combination has shown improved survival in the landmark CheckMate (CM)-743 trial, evidence from real-world settings remains limited.</p><p><strong>Methods: </strong>In this retrospective, multicenter study, the outcome and safety data for 135 consecutive patients with first-line nivolumab/ipilimumab were evaluated among 1,575 adult patients with PM from 12 German cancer centers. Radiologic response and progression were analyzed according to the revised modified RECIST criteria.</p><p><strong>Results: </strong>The median overall survival (OS) was 13.1 months for the unselected real-world cohort, and 15.5 months for CM-743-eligible patients (16.7 months for the non-epithelioid and 10 months for the epithelioid subtypes). Patients who experienced partial responses to nivolumab/ipilimumab had significantly longer survival than those without (24 months vs. 10.3 months; p = 0.00026). 37 % of patients experienced immune-related adverse events (irAEs), among whom 58 % had grade 3/4 toxicity. IrAEs of any grade were associated with longer survival (17.3 months vs. 11.7 months for patients without irAEs; p = 0.022). Furthermore, grade 1/2 irAEs were associated with even better outcomes when compared to grade 3/4 toxicities (22.7 months vs. 16.7 months median OS) and absence of toxicity (p < 0.0167 for trend).</p><p><strong>Conclusions: </strong>Overall survival with first-line nivolumab/ipilimumab in the real-world setting is comparable to the CM-743 results among trial-eligible patients, especially with non-epithelioid tumors, but shorter for the unselected cohort. IrAEs, in particular those of low-grade, were associated with better outcomes. In the absence of predictive biomarkers and with few therapeutic options available, both dual checkpoint blockade and platinum-pemetrexed chemotherapy remain viable first-line regimens.</p>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"207 ","pages":"108702"},"PeriodicalIF":4.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144804405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the editor: Critical analysis of the CANFOUR trial on nadunolimab in advanced NSCLC.","authors":"Zongyu Yang, Songjie Liao","doi":"10.1016/j.lungcan.2025.108703","DOIUrl":"10.1016/j.lungcan.2025.108703","url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"207 ","pages":"108703"},"PeriodicalIF":4.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144812206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of recruitment method on informed decision-making in lung cancer screening in the 4-IN-THE-LUNG-RUN trial.","authors":"Juul Hubert, Dana Moldovanu, Isabelle van den Bosch, Koen de Nijs, Kevin Ten Haaf, Matthijs Oudkerk, Harry J de Koning, Carlijn M van der Aalst","doi":"10.1016/j.lungcan.2025.108686","DOIUrl":"10.1016/j.lungcan.2025.108686","url":null,"abstract":"<p><strong>Objectives: </strong>It is relatively unknown how to inform individuals about lung cancer screening to enable informed decision-making (IDM). This study aims to determine the level of IDM across different recruitment methods among participants invited for the 4-IN-THE-LUNG-RUN trial, the European implementation trial for lung cancer screening.</p><p><strong>Methods: </strong>A 23-item online questionnaire related to decision-relevant knowledge was sent to 848 Dutch men and women, aged 60-79 years, who were randomised in 4-IN-THE-LUNG-RUN. Respondents were considered to have sufficient knowledge when answering at least 12 items correctly. Informed choice was determined as 1) having sufficient knowledge and 2) consistency between intention to be screened and actual participation.</p><p><strong>Results: </strong>Participants were recruited between July 2024 and August 2024. Of 386 respondents (45.5 %) with fully completed questionnaires, 327 (84.7 %) had sufficient knowledge and made an informed decision, 283 (85.2 %) of the screened participants (n = 332) did so. Knowledge scores increased with the level of tailoring as compared to standard paper information (p = 0.015). While 78.1 % from the standard paper group made an informed choice, 89.0 % from the tailored group did so (p = 0.088). IDM was comparable among the socioeconomic status (SES) groups: 79.8 % (95/119) of the participants in the lower, 84.5 % (93/110) in the middle, and 88.5 % (139/157) in the high SES group made an informed decision (p = 0.138). No sex-related differences were found in informed decision-making: 196 out of 231 males (84.8 %) versus 131 out of 155 females (84.5 %), p = 0.929. Even if assumed that all responders with incomplete questionnaires did have insufficient knowledge, 69.6 % were able to make an informed decision.</p><p><strong>Conclusion: </strong>The manner in which participants are informed contributes to the extent to which they can make an informed decision. A more tailored approach leads to improved knowledge, which facilitates IDM. The results indicate an equivalent level of IDM across different SES and sex groups.</p>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"207 ","pages":"108686"},"PeriodicalIF":4.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144804406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic impact and characteristics of ROS1 fusion in patients with surgically resected lung adenocarcinoma","authors":"Juemin Yu ,&nbsp;Xinchen Shen ,&nbsp;Jialiang Wen ,&nbsp;Tao Chen,&nbsp;Yunlang She,&nbsp;Deping Zhao,&nbsp;Chang Chen,&nbsp;Jiajun Deng","doi":"10.1016/j.lungcan.2025.108743","DOIUrl":"10.1016/j.lungcan.2025.108743","url":null,"abstract":"<div><h3>Objective</h3><div>We aimed to investigate the prognostic significance of <em>ROS1</em> fusion in surgically resected lung adenocarcinoma (LUAD).</div></div><div><h3>Materials and methods</h3><div>Consecutive patients who underwent complete resection and <em>ROS1</em> testing between 2015 and 2020 were included. Propensity score matching (1:2) was applied to balance baseline characteristics. Disease-free survival (DFS), overall survival (OS), and cumulative incidence of recurrence (CIR) were compared overall and by TNM stage. Recurrence patterns and post-recurrence survival (PRS) in <em>ROS1</em> fusion-positive patients were also analyzed.</div></div><div><h3>Results</h3><div>Overall, 16,779 patients met the inclusion criteria (216 <em>ROS1</em> fusion-positive and 16,563 <em>ROS1</em> fusion-negative). After matching, 216 <em>ROS1</em> fusion-positive and 432 <em>ROS1</em> fusion-negative patients were included in survival analysis. In the overall cohort, the <em>ROS1</em> fusion-positive group had similar DFS (5-year: 72.7 % vs. 66.4 %; p = 0.074) and OS (5-year: 87.6 % vs. 80.7 %; p = 0.055) compared with the<!--> <em>ROS1</em> <!-->fusion-negative group. Subgroup analysis showed that <em>ROS1</em> fusion was associated with better DFS (hazard ratio [HR], 0.609; 95 % confidence interval [CI], 0.376–0.986; p = 0.043) and OS (HR, 0.481; 95 % CI, 0.242–0.958; p = 0.037) in stage I, with similar outcomes in stages II–III. In addition, recurrence patterns and CIR analyses were consistent with these findings. Among patients who experienced recurrence, ROS1 tyrosine kinase inhibitors (TKIs) significantly improved PRS (median PRS: 65 vs. 20 months; p &lt; 0.001). In multivariate Cox regression analysis, ROS1-TKI therapy remained an independent protective factor for PRS (HR = 0.259; 95 % CI, 0.103–0.647; p = 0.004).</div></div><div><h3>Conclusion</h3><div><em>ROS1</em> fusion was associated with better prognosis in stage I LUAD, and ROS1-TKI therapy conferred a survival advantage after recurrence.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"208 ","pages":"Article 108743"},"PeriodicalIF":4.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144989097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial.","authors":"Anne-Marie C Dingemans, Konstantinos Syrigos, Lorenzo Livi, Astrid Paulus, Sang-We Kim, Yuanbin Chen, Enriqueta Felip, Frank Griesinger, Kadoaki Ohashi, Gerard Zalcman, Brett G M Hughes, Jens Benn Sørensen, Normand Blais, Carlos G M Ferreira, Colin R Lindsay, Rafal Dziadziuszko, Patrick J Ward, Cynthia Chinedu Obiozor, Yang Wang, Solange Peters","doi":"10.1016/j.lungcan.2025.108683","DOIUrl":"10.1016/j.lungcan.2025.108683","url":null,"abstract":"<p><strong>Objectives: </strong>To assess the efficacy and safety of sotorasib in patients with brain metastases using data from the phase 3 CodeBreaK 200 study, which evaluated sotorasib in adults with pretreated advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC).</p><p><strong>Materials and methods: </strong>Patients with KRAS G12C-mutated NSCLC who progressed after platinum-based chemotherapy and checkpoint inhibitor therapy were randomized 1:1 to sotorasib or docetaxel. An exploratory post-hoc analysis evaluated central nervous system (CNS) progression-free survival (PFS) and time to CNS progression in patients with treated and stable brain metastases at baseline. Measures were assessed by blinded independent central review per study-modified Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria.</p><p><strong>Results: </strong>Of the patients randomly assigned to receive sotorasib (n=171) or docetaxel (n=174), baseline CNS metastases were present in 40 (23%) and 29 (17%) patients, respectively. With a median follow-up of 20.0 months for this patient subgroup, median CNS PFS was longer with sotorasib compared with docetaxel (9.6 vs 4.5 months; hazard ratio, 0.43 [95% CI, 0.20-0.92]; P=0.02). Among patients with baseline treated CNS lesions of ≥10 mm, the percentage of patients who achieved CNS tumor shrinkage of ≥30% was two-fold higher with sotorasib than docetaxel (33.3% vs 15.4%). Treatment-related adverse events among patients with CNS lesions at baseline were consistent with those of the overall study population.</p><p><strong>Conclusions: </strong>These results suggest intracranial activity with sotorasib complements the overall PFS benefit observed with sotorasib vs docetaxel, with safety outcomes similar to those in the general CodeBreaK 200 population.</p><p><strong>Clinical trials registration number: </strong>NCT04303780.</p>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"207 ","pages":"108683"},"PeriodicalIF":4.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144799528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Communication about personal values of patients with advanced lung cancer in the hospital: results of a mixed-methods study","authors":"Matthias Villalobos ,&nbsp;Jan Ole Ludwig ,&nbsp;Mara König ,&nbsp;Laura Unsöld ,&nbsp;Anja Siegle ,&nbsp;Michael Thomas","doi":"10.1016/j.lungcan.2025.108729","DOIUrl":"10.1016/j.lungcan.2025.108729","url":null,"abstract":"<div><h3>Background</h3><div>Guidelines recommend to discuss the treatment and care goals of patients with advanced cancer in alignment with their values and preferences, yet this approach is often not adequately implemented in hospitals. To explore the personal values of patients with metastatic lung cancer and how they communicate them to physicians, a mixed-methods study was conducted at a German University Lung Cancer Center.</div></div><div><h3>Methods</h3><div>The study included quantitative data from 66 patients with metastatic lung cancer using the Human Values Scale, a group comparison after propensity score matching with the German cohort from the 9th European Social Survey, semi-structured in-depth interviews (n = 17), qualitative content analysis, and integration of the data using side-by-side display.</div></div><div><h3>Results</h3><div>The quantitative analysis showed that patients prioritized the value dimensions of self-transcendence (universalism, benevolence; p = 0.02) and openness to change (self-direction, stimulation; p = 0.03), with a shift toward stronger self-direction in more advanced disease. In contrast, values related to conservation (conformity, tradition, security; p = 0.04) and self-enhancement (power, achievement; p = 0.02) were less important. Despite these stated preferences, qualitative data revealed that personal values and existential concerns were largely overlooked in clinical encounters. Patients often accepted physicians’ treatment recommendations without question, suggesting a gap in addressing their values and preferences.</div></div><div><h3>Conclusions</h3><div>Our findings highlight the need for physicians to take a proactive role in discussing patient values and empowering them in decision-making. These insights can inform the development of value assessment tools and interventions to improve shared decision-making and goal-concordant care.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"208 ","pages":"Article 108729"},"PeriodicalIF":4.4,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144922422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lineage-specific transcription factor landscape of thymic neuroendocrine tumors","authors":"Seiji Omura ,&nbsp;Yutaka Kurebayashi ,&nbsp;Junko Hamamoto ,&nbsp;Hideki Terai ,&nbsp;Tomohiro Imoto ,&nbsp;Mikito Suzuki ,&nbsp;Kazuo Nakagawa ,&nbsp;Takahiro Suzuki ,&nbsp;Takao Shigenobu ,&nbsp;Akira Yoshizu ,&nbsp;Chihaya Maeda ,&nbsp;Masahiro Kaji ,&nbsp;Yu Okubo ,&nbsp;Shigeki Suzuki ,&nbsp;Kyohei Masai ,&nbsp;Kaoru Kaseda ,&nbsp;Koichi Fukunaga ,&nbsp;Hiroyuki Yasuda ,&nbsp;Keisuke Asakura","doi":"10.1016/j.lungcan.2025.108731","DOIUrl":"10.1016/j.lungcan.2025.108731","url":null,"abstract":"<div><h3>Introduction</h3><div>Thymic neuroendocrine tumors (TNETs) are rare malignancies characterized by aggressive clinical behavior and limited therapeutic options. In small cell lung cancer (SCLC), molecular subtypes based on the expression of lineage-defining transcription factors (TFs)—ASCL1, NEUROD1, POU2F3, and YAP1—have been proposed. However, the TF landscape of TNETs remains poorly defined. Given the pathological similarities among neuroendocrine tumors across organs, we aimed to investigate whether the TF-based classification system used in SCLC is applicable to TNETs.</div></div><div><h3>Methods</h3><div>Sixteen pathologically confirmed TNETs—including large cell neuroendocrine carcinoma (LCNEC), thymic small cell carcinoma (TSCC), atypical carcinoid (AC), and typical carcinoid (TC)—were retrospectively analyzed. Immunohistochemistry was performed to evaluate classical neuroendocrine (NE) markers (synaptophysin, chromogranin A, CD56) and TFs (ASCL1, NEUROD1, POU2F3, YAP1). H-scores were calculated, and tumors were categorized according to TFs expression profiles.</div></div><div><h3>Results</h3><div>Synaptophysin was strongly expressed in all cases, while chromogranin A and CD56 showed variable expression, with reduced levels in LCNEC and TSCC. The combined NE score was significantly higher in carcinoid tumors compared to LCNEC and TSCC. For TFs, ASCL1 expression was observed in 93.8 % of cases, whereas NEUROD1 and POU2F3 were rarely or not expressed. YAP1 expression was confined to LCNEC cases, all of which co-expressed ASCL1 and YAP1. Based on H-scores, TNETs were classified into three subgroups: (1) ASCL1-positive/YAP1-negative (n = 12, 75 %), (2) ASCL1/YAP1 double-positive (n = 3, 19 %), and (3) double-negative (n = 1, 6 %).</div></div><div><h3>Conclusion</h3><div>This study reveals molecular heterogeneity among TNETs. Notably, ASCL1 and YAP1 co-expression characterizes all LCNEC cases, making a distinct TF landscape in high-grade TNETs.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"208 ","pages":"Article 108731"},"PeriodicalIF":4.4,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144917787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DuTOC: The prospective Dutch Thoracic Oncology Cohort: A nationwide infrastructure to collect clinical data, PROMS and bio-material to support thoracic oncology studies","authors":"W.K. de Jong ,&nbsp;F.T.A. van der Velde ,&nbsp;A. Keijser ,&nbsp;H.J.M. Groen ,&nbsp;A.S.R. van Lindert ,&nbsp;G.R. Vink ,&nbsp;L.E.L. Hendriks ,&nbsp;M.M. van den Heuvel ,&nbsp;on behalf of the DuTOC scientific committee","doi":"10.1016/j.lungcan.2025.108728","DOIUrl":"10.1016/j.lungcan.2025.108728","url":null,"abstract":"<div><div>The Dutch Thoracic Oncology Cohort (DuTOC) is a nationwide cohort for patients with thoracic malignancies collecting patient characteristics, quality of life and biomaterials after informed consent of the patient. With this data and material DuTOC is a solid infrastructure for retrospective and prospective studies involving treatment, (molecular) diagnostics, quality control, biomarkers and translational research and quality of life.</div><div>DuTOC is initiated by the Dutch Association of Pulmonologists and is a collaboration of all clinicians involved in cancer-care and other stakeholders in the field of thoracic malignancies such as patient advocacies, health regulatory agencies, cancer registries and pharmaceutical companies.</div><div>DuTOC has the ambition to automate real-time data acquisition. This minimizes the workload of the research staff and facilitates the transition to a self-learning health care system based on real-time data, incorporating long-term longitudinal assessment of patient reported outcome measurements. Therefore, DuTOC will play a crucial role in the improvement of the care for patients with thoracic malignancies.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"208 ","pages":"Article 108728"},"PeriodicalIF":4.4,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144912002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early pseudo-progression of brain metastases following tarlatamab therapy in relapsed small cell lung cancer","authors":"Naoki Shijubou ,&nbsp;Toshiyuki Sumi ,&nbsp;Taiki Ishigooka ,&nbsp;Taeka Naraoka ,&nbsp;Kazuya Takeda ,&nbsp;Yuichi Yamada ,&nbsp;Hirofumi Chiba","doi":"10.1016/j.lungcan.2025.108730","DOIUrl":"10.1016/j.lungcan.2025.108730","url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"207 ","pages":"Article 108730"},"PeriodicalIF":4.4,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144907578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}